|Bid||0.00 x 1000|
|Ask||0.00 x 800|
|Day's Range||19.76 - 19.80|
|52 Week Range||18.35 - 22.24|
|PE Ratio (TTM)||N/A|
|Beta (3Y Monthly)||0.98|
|Expense Ratio (net)||0.30%|
Wall Street analysts are estimating that GlaxoSmithKline will report revenues of ~8.02 billion pounds for the third quarter of 2018. GlaxoSmithKline stock has increased ~8.5% over the last 12 months and ~10.8% year-to-date. Analyst recommendations show a 12-month target price of $44.31 per share compared to its last price of $39.32 on October 26.
Wall Street analysts estimate that Novartis will report revenues of $13.4 billion during the fourth quarter of 2018, a 4.0% increase in year-over-year revenues as compared to $12.9 billion during the fourth quarter of 2017. The earnings-per-share is estimated at $1.29 during the fourth quarter of 2018. Analysts estimate the net income margin to increase to 22.1% during the fourth quarter of 2018 as compared to 21.8% during the fourth quarter of 2017.
Novartis’s (NVS) Innovative Medicines business includes prescription products from two business units: Novartis Pharmaceuticals and Novartis Oncology. The Innovative Medicines business contributed over 67.2% of the total revenues for Novartis and saw 6% growth in year-over-year (or YoY) revenues to ~$8.6 billion during the third quarter of 2018.
Novartis’s (NVS) Innovative Medicines segment includes prescription products from two business units: Novartis Pharmaceuticals and Novartis Oncology.
Headquartered in Basel, Switzerland, Novartis (NVS) specializes in research and development, manufacturing, and marketing of a broad range of healthcare products. The company’s three segments are Innovative Medicines, Sandoz, and Alcon. Sandoz is Novartis’s generics business, and Alcon is its eye care business.
GlaxoSmithKline (GSK) has three business segments: the Pharmaceuticals segment, the Vaccines segment, and the Consumer Healthcare segment. We’ll discuss how the company’s segments performed in this article.
Novartis (NVS) announced today, September 6, that it has agreed to sell select portions of its Sandoz US portfolio to Aurobindo Pharma USA for $0.9 billion in cash and $0.1 billion in potential earn-outs. The select portions include the Sandoz US dermatology business and the generic US oral solids business. The deal includes ~300 products and additional development programs that will be transferred from Sandoz’s US portfolio to Aurobindo.
Sandoz is Novartis’s (NVS) generics business and is a market leader in differentiated generics. Sandoz reported nearly flat revenues at ~$2.46 billion in Q2 2018 compared to $2.45 billion in the second quarter of 2017. Revenue growth was driven by a 2% favorable impact of foreign exchange, offset by a 2% decline in operating revenues.
Novartis (NVS) announced on August 23 that its SOLAR-1 trial, a Phase 3 trial evaluating investigational drug BYL719 (alpelisib) in combination with fulvestrant, has met its primary endpoint.